Company Overview of The Wistar Institute
The Wistar Institute is an educational institution.
3601 Spruce Street
Philadelphia, PA 19104
Key Executives for The Wistar Institute
President and Chief Executive Officer
Director of Communications
Chief Scientific Officer and Director of Cancer Center
Compensation as of Fiscal Year 2013.
The Wistar Institute Key Developments
BioTime, Inc.'s Subsidiary OncoCyte Corporation and The Wistar Institute to Collaboratively Develop Cancer Diagnostics
Oct 15 13
BioTime Inc. and its subsidiary OncoCyte Corporation announced that OncoCyte has entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to collaboratively develop lung cancer diagnostic products. As part of the collaboration, Wistar investigators are conducting a multi-center patient study in which they are assessing gene expression patterns in blood cells of patients with malignant versus non-malignant lung disease. OncoCyte scientists will analyze blood samples obtained from patients in the study to determine levels of tumor-associated proteins using its proprietary PanC-Dx(TM) diagnostic tests. PanC-Dx(TM) is a class of non-invasive cancer diagnostics based on a proprietary set of cancer markers characterized, in part, by broad gene expression patterns in numerous cancer types. The inclusion of the PanC-Dx(TM) markers in Wistar's ongoing multi-center study may allow OncoCyte to more rapidly develop a diagnostic test for lung cancer to be marketed in the U.S. and other countries. The performance of markers tested in the study in determining the presence or the progression of disease in various categories of patients may determine the specific nature of the lung cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue. OncoCyte will have an option to exclusively license any inventions, discoveries or technology developed by Wistar, or by OncoCyte using Wistar technology, in the course of the collaborative research. OncoCyte has previously published in peer-reviewed scientific journals data relating to two PanC-Dx(TM) markers: COL10A1, a marker associated with the vasculature of numerous solid tumors, and FSIP1, a marker unique to breast cancer.
The Wistar Institute Announces CFO Changes
Aug 7 13
The Wistar Institute named Joseph G. Trainor as its new chief financial officer. Trainor succeeds Larry Keinath, who is planning to retire later this year but will stay at the Philadelphia biomedical research center through August to help with the transition. Trainor spent the past 18 years at the University of the Sciences - most recently as the Philadelphia college's chief financial officer, chief compliance officer and senior vice president of finance. Before that, Trainor was comptroller and acting-treasurer at Drexel University.
The Wistar Institute Welcomes Van Billet, Joseph Goldblum and Art Pappas as Board Members
Nov 16 12
The Wistar Institute announced that it recently welcomed Van Billet, Joseph Goldblum and Art Pappas to its board of trustees. Currently, Art Pappas serves as managing partner at Pappas Ventures. Pappas currently serves on the board of directors for Afferent Pharmaceuticals, CardioDx, Chimerix and TyRx Pharma. Pappas serves on the North Carolina Biotechnology Center's Board of Directors and is a member of the National Venture Capital Association (NVCA) Medical Industry Group Advisory Board.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries